Atrium Therapeutics
RNA
155 hedge funds and large institutions have $193M invested in Atrium Therapeutics in 2026 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 47 increasing their positions, 35 reducing their positions, and 46 closing their positions.
34% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 35
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3% less capital invested
Capital invested by funds: $198M → $193M (-$5.55M)
2.88% less ownership
Funds ownership: 86.67% → 83.79% (-2.9%)
5% less funds holding
Funds holding: 163 → 155 (-8)
13% less first-time investments, than exits
New positions opened: 40 | Existing positions closed: 46
92% less call options, than puts
Call options by funds: $935K | Put options by funds: $11.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Sessa Capital
New York
|
+$12.4M |
| 2 |
CL
CRCM LP
San Francisco,
California
|
+$8.38M |
| 3 |
BlackRock
New York
|
+$3.16M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$2.25M |
| 5 |
Two Sigma Investments
New York
|
+$2.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$11.6M |
| 2 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$8.06M |
| 3 |
OCAI
O'Connor Alternative Investments
New York
|
-$7.73M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$4.67M |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$3.52M |
RNA Hedge Fund Activity: Q2 2026 in Review
155 of the 8,317 institutional investors tracked by Wall St. Rank reported a position in Atrium Therapeutics (RNA) for Q2 2026, worth a combined $193M — down 2.8% from $198M a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of RNA and 40 opened new positions — a net loss of 6 holders — while 35 trimmed existing stakes and 47 added.
The largest buyer was Sessa Capital, adding an estimated $12.4M. The largest seller was RA Capital Management, exiting entirely with an estimated $11.6M sold.
- 155 institutional investors held Atrium Therapeutics (RNA) as of Q2 2026, down from 163 in Q1 2026.
- Funds reported $193M of Atrium Therapeutics stock for Q2 2026, down 2.8% quarter-over-quarter.
- 40 funds opened new Atrium Therapeutics positions in Q2 2026 and 46 closed out, a net change of -6 holders.
- The largest Atrium Therapeutics buyer in Q2 2026 was Sessa Capital, an estimated $12.4M added.
- The largest Atrium Therapeutics seller in Q2 2026 was RA Capital Management, an estimated $11.6M sold.
Based on aggregated 13F filings for Q2 2026.